EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

An open‐label phase II study: The efficiency and safety of anlotinib + eribulin in patients with HER2 ‐negative metastatic breast cancer

Xinyu Wu iD, Fei Qu, Yijia Hua, Rongrong Lu, Nan Jin, Yan Liang, Chunxiao Sun, Fan Yang, Wei Li, Xiang Huang, Yongmei Yin iD

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70079 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Xinyu Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: Ketones, Furans, Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Beijing Xisike Clinical Oncology Research Foundation, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This research (NCT04624711) evaluated the efficacy and safety of eribulin plus anlotinib in patients with HER2‐negative metastatic breast cancer (mBC) and explored the potential synergistic benefits of this combination. A total of 70 women with HER2‐negative breast cancer who had previously undergone anthracycline‐ or taxane‐based therapies were enrolled. Hormone receptor‐positive patients had also received CDK4/6 (Cyclin‐dependent kinase 4/6) inhibitor‐based endocrine therapy. All patients were treated with eribulin mesylate (1.4 mg/m 2 , administered intravenously on days 1 and 8) and anlotinib (12 mg orally, once daily on days 1–14) in 21‐day cycles. The median progression‐free survival (mPFS) was 7.00 months, with an objective response rate (ORR) of 50.00% and a disease control rate (DCR) of 94.29%. Patients with fewer than two visceral metastases exhibited a significantly longer median PFS than those with multiple visceral metastases (8.93 months vs. 6.90 months, p = 0.0337). The most common treatment‐related adverse events (TRAEs) were neutropenia (67.14%) and leukopenia (68.57%), with 41.43% and 27.14% of patients experiencing grade 3/4 hematologic toxicities, respectively. These findings suggest that the combination of eribulin and anlotinib demonstrated encouraging efficacy and a manageable safety profile, offering a potential therapeutic option for patients with HER2‐negative mBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetonesFuransBreast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsQuinolinesIndolesHumansFemaleMiddle AgedErb-b2 Receptor Tyrosine KinasesAdultAgedNeoplasm MetastasisProgression-Free SurvivalPolyether Polyketides

Stichwörter der Autor:innen

HER2‐negative advanced breast canceranlotinibcombination therapyeribulin

Substanzen

KetonesFuransQuinolinesErb-b2 Receptor Tyrosine KinasesIndolesPolyether PolyketideseribulinanlotinibERBB2 protein, human

Autor:innen und Institutionen

  • Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Department of Oncology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, China.
  • Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

ORCID-Profile: Xinyu Wu, Yongmei Yin

Förderung

  • Beijing Xisike Clinical Oncology Research Foundation
  • National Natural Science Foundation of China

Zitieren

APA

Wu, X., Qu, F., Hua, Y., Lu, R., Jin, N., Liang, Y., Sun, C., Yang, F., Li, W., Huang, X., & Yin, Y. (2026). An open‐label phase II study: The efficiency and safety of anlotinib + eribulin in patients with HER2 ‐negative metastatic breast cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.70079

Vancouver

Wu X, Qu F, Hua Y, Lu R, Jin N, Liang Y, et al. An open‐label phase II study: The efficiency and safety of anlotinib + eribulin in patients with HER2 ‐negative metastatic breast cancer. International Journal of Cancer. 2026. doi:10.1002/ijc.70079

BibTeX
@article{Wu2026,
  author = {Wu, Xinyu and Qu, Fei and Hua, Yijia and Lu, Rongrong and Jin, Nan and Liang, Yan and Sun, Chunxiao and Yang, Fan and Li, Wei and Huang, Xiang and Yin, Yongmei},
  title = {An open‐label phase II study: The efficiency and safety of anlotinib + eribulin in patients with HER2 ‐negative metastatic breast cancer},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70079}
}
Kostenlos starten →